Shares of ImmuPharma plc (LON:IMM – Get Free Report) were up 86.7% during trading on Thursday . The company traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.24 ($0.03). Approximately 12,117,709 shares traded hands during mid-day trading, an increase of 314% from the average daily volume of 2,929,006 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Performance
The company has a market cap of £8.75 million, a P/E ratio of -210.00 and a beta of 1.53. The business’s 50-day moving average price is GBX 1.36 and its 200 day moving average price is GBX 1.63.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Further Reading
- Five stocks we like better than ImmuPharma
- 3 Fintech Stocks With Good 2021 Prospects
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Compound Interest and Why It Matters When Investing
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
